JP2017514787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514787A5 JP2017514787A5 JP2016553489A JP2016553489A JP2017514787A5 JP 2017514787 A5 JP2017514787 A5 JP 2017514787A5 JP 2016553489 A JP2016553489 A JP 2016553489A JP 2016553489 A JP2016553489 A JP 2016553489A JP 2017514787 A5 JP2017514787 A5 JP 2017514787A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- april
- composition
- variant
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000021161 Plasma cell disease Diseases 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 102000001493 Cyclophilins Human genes 0.000 claims description 2
- 108010068682 Cyclophilins Proteins 0.000 claims description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000004333 gold (food color) Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403481A GB201403481D0 (en) | 2014-02-27 | 2014-02-27 | Chimeric antigen receptor |
| GB1403479.7 | 2014-02-27 | ||
| GB201403479A GB201403479D0 (en) | 2014-02-27 | 2014-02-27 | Molecule |
| GB1403481.3 | 2014-02-27 | ||
| GB1409759.6 | 2014-06-02 | ||
| GB201409761A GB201409761D0 (en) | 2014-06-02 | 2014-06-02 | Chimeric antigen receptor |
| GB201409759A GB201409759D0 (en) | 2014-06-02 | 2014-06-02 | Molecule |
| GB1409761.2 | 2014-06-02 | ||
| PCT/GB2015/050557 WO2015128653A2 (en) | 2014-02-27 | 2015-02-26 | Ligand |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107701A Division JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Division JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514787A JP2017514787A (ja) | 2017-06-08 |
| JP2017514787A5 true JP2017514787A5 (OSRAM) | 2018-02-15 |
| JP6556156B2 JP6556156B2 (ja) | 2019-08-07 |
Family
ID=52633311
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553489A Expired - Fee Related JP6556156B2 (ja) | 2014-02-27 | 2015-02-26 | Ａｐｒｉｌバリアント |
| JP2017107701A Expired - Fee Related JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Pending JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107701A Expired - Fee Related JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Pending JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10752665B2 (OSRAM) |
| EP (2) | EP3243831A1 (OSRAM) |
| JP (3) | JP6556156B2 (OSRAM) |
| CN (1) | CN106414502A (OSRAM) |
| AU (1) | AU2015221933B2 (OSRAM) |
| CA (1) | CA2939411A1 (OSRAM) |
| ES (1) | ES2737690T3 (OSRAM) |
| WO (1) | WO2015128653A2 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| ES2737690T3 (es) | 2014-02-27 | 2020-01-15 | Ucl Business Ltd | Variantes de APRIL |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| RU2706582C2 (ru) | 2015-04-13 | 2019-11-19 | Пфайзер Инк. | Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток |
| KR102497013B1 (ko) | 2016-06-07 | 2023-02-20 | 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 | Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포 |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| CN108277205B (zh) * | 2016-12-30 | 2022-12-20 | 四川大学 | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 |
| CA3079264A1 (en) * | 2017-10-18 | 2019-04-25 | Intrexon Corporation | Polypeptide compositions comprising spacers |
| WO2019086573A1 (en) | 2017-11-01 | 2019-05-09 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 antigen-binding molecules |
| GB201720426D0 (en) * | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
| EP3737688A4 (en) * | 2018-01-10 | 2021-11-03 | The General Hospital Corporation | IMMUNE CELLS EXPRESSING A CHEMICAL ANTIGENIC RECEPTOR |
| US20200054675A1 (en) * | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| CA3103610A1 (en) * | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| WO2020247618A1 (en) * | 2019-06-04 | 2020-12-10 | The General Hospital Corporation | Antibodies and chimeric antigen receptors that target taci |
| CN110642953B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向bcma的t细胞受体融合蛋白和应用 |
| EP4384193A2 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| US20240425820A1 (en) | 2021-08-11 | 2024-12-26 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| JP2024534772A (ja) | 2021-08-11 | 2024-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 同種異系細胞療法用の遺伝子改変細胞 |
| IL315000A (en) | 2022-02-17 | 2024-10-01 | Sana Biotechnology Inc | Engineered cd47 proteins and uses thereof |
| WO2024097315A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Cell therapy products and methods for producing same |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| IL150755A0 (en) * | 2000-02-16 | 2003-02-12 | Genentech Inc | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| WO2004020593A2 (en) | 2002-08-30 | 2004-03-11 | Incyte Corporation | Immune response associated proteins |
| WO2004089982A2 (en) | 2003-01-06 | 2004-10-21 | Xencor | April variants and methods thereof |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050003480A1 (en) * | 2003-01-06 | 2005-01-06 | Xencor | April variants and methods thereof |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
| US20140105915A1 (en) | 2011-05-27 | 2014-04-17 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| MX394639B (es) | 2012-04-11 | 2025-03-24 | Us Health | Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b |
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| ES2737690T3 (es) | 2014-02-27 | 2020-01-15 | Ucl Business Ltd | Variantes de APRIL |
| US20190352409A1 (en) | 2016-11-11 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
-
2015
- 2015-02-26 ES ES15708871T patent/ES2737690T3/es active Active
- 2015-02-26 CN CN201580010156.0A patent/CN106414502A/zh active Pending
- 2015-02-26 WO PCT/GB2015/050557 patent/WO2015128653A2/en not_active Ceased
- 2015-02-26 AU AU2015221933A patent/AU2015221933B2/en not_active Ceased
- 2015-02-26 JP JP2016553489A patent/JP6556156B2/ja not_active Expired - Fee Related
- 2015-02-26 EP EP17172770.4A patent/EP3243831A1/en not_active Withdrawn
- 2015-02-26 US US15/121,644 patent/US10752665B2/en not_active Expired - Fee Related
- 2015-02-26 CA CA2939411A patent/CA2939411A1/en not_active Abandoned
- 2015-02-26 EP EP15708871.7A patent/EP3110838B1/en active Active
-
2017
- 2017-05-26 US US15/606,660 patent/US10611811B2/en not_active Expired - Fee Related
- 2017-05-31 JP JP2017107701A patent/JP6707496B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-30 JP JP2019014039A patent/JP2019068855A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514787A5 (OSRAM) | ||
| Ramos et al. | In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas | |
| US20230081443A1 (en) | Anti-il1rap antibodies | |
| JP2016538830A5 (OSRAM) | ||
| JP2025032089A (ja) | 腫瘍微小環境を標的とするキメラ抗原受容体 | |
| Cook et al. | Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions | |
| JP2018508215A5 (OSRAM) | ||
| JP2017508466A5 (OSRAM) | ||
| Low et al. | Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| JP2020500542A5 (OSRAM) | ||
| PH12015500113A1 (en) | Anti-kit antibodies and uses thereof | |
| JP2017501129A5 (OSRAM) | ||
| Fichtner et al. | Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset | |
| JP2017509342A5 (OSRAM) | ||
| JP2017515460A5 (OSRAM) | ||
| JP2017522903A5 (OSRAM) | ||
| JP2017526361A5 (OSRAM) | ||
| Larson et al. | Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma | |
| AU2015274504A1 (en) | Use of VISTA agonists and antagonists to suppress or enhance humoral immunity | |
| WO2012103165A3 (en) | Anti-kit antibodies and uses thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| RU2016124163A (ru) | Сконструированные высокоаффинные t-клеточные рецепторы человека | |
| JP2013538796A5 (OSRAM) | ||
| US20240352136A1 (en) | Antibodies for the treatment of aml |